GPC3 and hepatocellular carcinoma: Zhao et al. [49] used the novel glypican-3, a membrane-bound heparin sulfate proteoglycan that is highly expressed in HCC but negative in the normal liver tissue, to bind to the specific aptamer to target the glypican-3 positive HCC specifically (Figure 4).